NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
43598-0344-90 | 43598-0344 | Imatinib | Imatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 13, 2018 | In Use | |
60505-3630-06 | 60505-3630 | Dasatinib | Dasatinib | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
54868-5427-01 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
63459-0177-14 | 63459-0177 | Omacetaxine Mepesuccinate | Synribo | 3.5 mg/mL | Chemotherapy | Plant Alkaloid | BCR-ABL | Subcutaneous | Nov 19, 2012 | Apr 30, 2024 | No Longer Used |
68180-0391-06 | 68180-0391 | IMATINIB | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jul 8, 2019 | In Use | |
43598-0604-30 | 43598-0604 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
00078-0649-30 | 00078-0649 | Imatinib Mesylate | Gleevec | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 23, 2014 | In Use | |
68382-0245-05 | 68382-0245 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
60687-0882-21 | 60687-0882 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 19, 2025 | In Use | |
60505-2901-09 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
72606-0557-01 | 72606-0557 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 6, 2019 | In Use | |
60505-3631-03 | 60505-3631 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
64679-0794-03 | 64679-0794 | imatinib mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 17, 2019 | In Use | |
50268-0427-12 | 50268-0427 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 24, 2017 | In Use | |
43598-0603-30 | 43598-0603 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
60505-2901-01 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
54868-5427-02 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
72606-0556-01 | 72606-0556 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 6, 2019 | In Use | |
59923-0723-90 | 59923-0723 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 1, 2020 | In Use | |
70377-0087-11 | 70377-0087 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
24338-0155-01 | 24338-0155 | Nilotinib | DANZITEN | 95.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 30, 2024 | In Use | |
00003-0524-11 | 00003-0524 | Dasatinib | Sprycel | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 27, 2006 | In Use | |
63629-2067-01 | 63629-2067 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | Mar 31, 2023 | No Longer Used |
54868-5427-00 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
65162-0795-09 | 65162-0795 | Imatinib | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use |
Found 11465 results — Export these results